Subscribe to Newsletter

Business & Regulation


Business & Regulation Standards & Regulation

Trump's New Push on Drug Pricing

| Rob Coker | 2 min read

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

Business & Regulation Profession

From Benchtop Chemist to CEO

| Stephanie Vine | 5 min read

Simon Tasker joined Colorcon as a bench chemist – and never left. Today, he’s the company’s CEO. Here’s how his career unfolded.

Business & Regulation Standards & Regulation

Disrupted Development

| Rob Coker | 3 min read

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

Business & Regulation Profession

The Blood Cancer Success Story: Part 2

| Stephanie Vine | 6 min read

Lore Gruenbaum discusses The Leukemia & Lymphoma Society, advances in blood cancers, and the role of nonprofits.

Business & Regulation Bioprocessing - Upstream & Downstream

ADC Innovation: The Road Ahead

| Rob Coker | 5 min read

ADCs have shown their promise, but the next step is realizing their potential.

Business & Regulation Standards & Regulation

FDA to Phase Out Animal Testing

| Rob Coker | 2 min read

FDA to phase out mandatory animal testing with human-relevant methods for drug development

Business & Regulation Standards & Regulation

Trump Speech Suggests Pharma Tariffs Incoming

| Stephanie Vine | 2 min read

Donald Trump threatens “major tariff” on pharmaceuticals.

Business & Regulation Standards & Regulation

Sitting Down With… The Past: Kowid Ho

| 3 min read

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Business & Regulation Profession

The Blood Cancer Success Story: Part 1

| Stephanie Vine | 7 min read

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.

Business & Regulation Standards & Regulation

Is the FDA About to Break?

| Stephanie Vine | 3 min read

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”


Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register